Valeant at 80% Buy Shows How Hard Skepticism Is for Wall Street

  • Eighteen buys and four holds when stock peaked in August
  • Lone bear is Veritas's Khmelnitsky, a former Israeli soldier

To see why Wall Street analysts were so bullish on Valeant Pharmaceuticals International Inc. before its stunning fall, you need to consider just how dangerous it was to be bearish.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.